Richard G Knowles
Overview
Explore the profile of Richard G Knowles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yasinska V, Gomez C, Kolmert J, Ericsson M, Pohanka A, James A, et al.
ERJ Open Res
. 2023 Oct;
9(5).
PMID: 37868143
Rationale: Patients with severe asthma are dependent upon treatment with high doses of inhaled corticosteroids (ICS) and often also oral corticosteroids (OCS). The extent of endogenous androgenic anabolic steroid (EAAS)...
2.
Sparreman Mikus M, Kolmert J, Andersson L, Ostling J, Knowles R, Gomez C, et al.
Eur Respir J
. 2021 Nov;
59(2).
PMID: 34737220
Rationale: Asthma phenotyping requires novel biomarker discovery. Objectives: To identify plasma biomarkers associated with asthma phenotypes by application of a new proteomic panel to samples from two well-characterised cohorts of...
3.
Mazein A, Ivanova O, Balaur I, Ostaszewski M, Berzhitskaya V, Serebriyskaya T, et al.
J Allergy Clin Immunol
. 2020 Dec;
147(3):853-856.
PMID: 33309742
No abstract available.
4.
Kolmert J, Gomez C, Balgoma D, Sjodin M, Bood J, Konradsen J, et al.
Am J Respir Crit Care Med
. 2020 Jul;
203(1):37-53.
PMID: 32667261
New approaches are needed to guide personalized treatment of asthma. To test if urinary eicosanoid metabolites can direct asthma phenotyping. Urinary metabolites of prostaglandins (PGs), cysteinyl leukotrienes (CysLTs), and isoprostanes...
5.
Brinkman P, Ahmed W, Gomez C, Knobel H, Weda H, Vink T, et al.
Eur Respir J
. 2019 Sep;
55(2).
PMID: 31515400
Introduction: Asthma is a heterogeneous condition, characterised by chronic inflammation of the airways, typically managed with inhaled bronchodilators and corticosteroids. In the case of uncontrolled asthma, oral corticosteroids (OCSs) are...
6.
Mazein A, Knowles R, Adcock I, Chung K, Wheelock C, Maitland-van der Zee A, et al.
Clin Exp Allergy
. 2018 Aug;
48(8):916-918.
PMID: 30133857
No abstract available.
7.
Mercer P, Abbott-Banner K, Adcock I, Knowles R
Clin Sci (Lond)
. 2014 Oct;
128(4):235-56.
PMID: 25328010
The 2nd Cross Company Respiratory Symposium (CCRS), held in Horsham, U.K. in 2012, brought together representatives from across the pharmaceutical industry with expert academics, in the common interest of improving...
8.
Slack R, Barrett V, Morrison V, Sturton R, Emmons A, Ford A, et al.
J Pharmacol Exp Ther
. 2012 Nov;
344(1):218-30.
PMID: 23131596
Vilanterol trifenatate (vilanterol) is a novel, long-acting β(2)-adrenoceptor (β(2)-AR) agonist with 24 h activity. In this study, we describe the preclinical pharmacological profile of vilanterol using radioligand binding and cAMP...
9.
Evans R, Nials A, Knowles R, Kidd E, Ford W, Broadley K
Pulm Pharmacol Ther
. 2012 Oct;
25(6):453-64.
PMID: 23046662
Pre-clinical evaluation of asthma therapies requires animal models of chronic airways inflammation, airway hyperresponsiveness (AHR) and lung remodelling that accurately predict drug effectiveness in human asthma. However, most animal models...
10.
Young R, Alderton W, Angell A, Beswick P, Brown D, Chambers C, et al.
Bioorg Med Chem Lett
. 2011 Apr;
21(10):3037-40.
PMID: 21482467
Heteroalicyclic carboxamidines were synthesised and evaluated as inhibitors of nitric oxide synthases. (2R)-2-Pyrrolidinecarboxamidine, in particular, was shown to be a highly potent in vitro (IC(50)=0.12 μM) and selective iNOS inhibitor...